Venture Medical, LLC has announced the closing of a strategic investment in Plasmacure B.V., the Dutch MedTech innovator behind PLASOMA, an award-winning cold plasma therapy for complex wound healing. The U.S.-based advanced wound care leader is spearheading a €6 million Series A round alongside Co-operatie VGZ, Noaber, Stichting Triade, and existing investors EIC Fund and OostNL.
Beyond the direct investment, Venture Medical is committing over $10 million to support PLASOMA's regulatory approval, reimbursement efforts, and U.S. market expansion, signaling significant confidence in the technology's potential to transform chronic wound care.
Clinical Performance Demonstrates Superior Outcomes
PLASOMA represents a novel approach to wound healing, delivering cold plasma through an intuitively designed pulser and specialized applicator that safely generates plasma from room air directly on the wound surface. The technology has demonstrated compelling clinical results, with recent trial data showing PLASOMA therapy achieved 2.5 times more wound closure than current standards of care.
"As a leading cause of amputations, sepsis, and many other severe complications, chronic wounds impact the lives of millions of patients while presenting a growing burden to our healthcare system," said John Schroeder, CEO of Venture Medical. "We see PLASOMA as a transformative technology that redefines what's possible in wound healing."
The cold plasma technology operates through dual mechanisms, providing powerful antimicrobial effects while simultaneously promoting tissue regeneration through various biological pathways. This dual action addresses key challenges in treating diabetic foot ulcers, venous leg ulcers, pressure ulcers, and other hard-to-heal wounds.
Addressing Growing Healthcare Burden
The investment comes as healthcare systems face mounting pressure from an aging population and increasing prevalence of chronic conditions that contribute to wound healing complications. Chronic wounds represent a significant clinical challenge, often leading to severe complications including amputations and life-threatening infections.
"As our population ages and chronic conditions become more prevalent, the need for effective wound healing solutions grows more urgent," Schroeder noted. "With PLASOMA, we're not just treating wounds, we're restoring access, independence, and dignity to patients who've been living without hope."
Strategic Partnership for Global Expansion
The funding will accelerate Plasmacure's global scale-up while establishing the foundation for U.S. FDA clearance, payer access, and national distribution through Venture Medical's extensive provider network. Founded in 2014 in the Netherlands, Plasmacure has developed PLASOMA as part of its mission to revolutionize wound care through safe, effective, and scalable technology.
"We are deeply motivated by the needs of the millions living with hard-to-heal wounds," said Bjorn Sprengers, CEO of Plasmacure. "With this investment and our new strategic partners, we are in a strong position to bring PLASOMA to more patients worldwide."
For Venture Medical, the investment aligns with its broader commitment to providing healthcare providers access to groundbreaking tools across biologics, diagnostics, durable medical equipment, and digital solutions. The partnership underscores the company's mission to empower providers to deliver healing without boundaries by introducing disruptive technologies that improve patient outcomes and expand access to state-of-the-art care.
PLASOMA offers a scalable, scientifically backed treatment option that could significantly impact the management of chronic wounds, potentially reducing the need for more invasive interventions and improving quality of life for patients with these challenging conditions.
